Krystal Biotech (KRYS) 10-K2021 FY Annual report

Filed: 27 Feb 23, 7:14am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: Academy, Aid, amplified, Amsterdam, attend, AUD, biopsy, birth, book, CA, calendar, campaign, carryback, chart, check, CHF, compassionate, consecutive, contingent, currency, deployed, Diego, dismissed, dispute, England, ESG, EUR, exhausted, fault, feedback, France, IRA, issuable, KPMG, LLP, media, mediation, Mexico, month, move, needle, Network, OTP, pause, PIP, pocket, precipitation, procedure, San, Science, sentiment, settle, settling, Singapore, stakeholder, startup, TDN, temperature, translation, unapproved, underway, underwritten, undiscounted, unspecified, Zug

Removed: ACA, ASU, automatically, BBA, Blueprint, communicate, consult, criticized, escrow, fill, fourth, generating, headcount, insider, instance, IP, legally, leveraging, licensure, listing, NSO, OCTGT, personal, Pty, released, rental, repaid, repurchase, ruled, simplex, varied, weakened, Wild

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

KRYS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the registration statements (No. 333-237983) on Form S-3ASR and (Nos. 333-269539, 333-220589, 333-252351, 333-262825) on Form S-8 of our reports dated February 27, 2023, with respect to the consolidated financial statements of Krystal Biotech, Inc. and the effectiveness of internal control over financial reporting.

/s/ KPMG LLP

Pittsburgh, Pennsylvania
February 27, 2023